Best value biological medicines are the clearest near term medicines productivity play in the NHS

Best value biological medicines are the clearest near term medicines productivity play in the NHS

This is why the most effective organisations treat best value biological adoption as a programme, not a memo. For a trust CFO or chief pharmacist, the practical playbook is relatively simple. First, select one or two priority molecules rather than trying to manage the whole future market at once. National prioritisation exists precisely to help systems concentrate effort where the value is largest and the implementation case is strongest. Pick the molecule, define the window, and make the expected benefits explicit. Second, build the case around pathway and capacity, not just price difference. Finance teams often reach too quickly for gross savings estimates. But the organisation may need clinic time, pharmacy support, homecare coordination or patient communications resource to switch at pace. NHS England explicitly acknowledges the need for resource enablement and supports financial arrangements that allow provider effort to be recognised. A realistic net value case will always outperform an inflated gross one. Third, agree a deployment model before launch. Which teams own identification of patients? Which clinical leaders will sponsor the switch? What will be the default for new starts? How will exceptions be managed? What is the expected adoption curve month by month? What reporting line will monitor progress? Organisations that answer these questions late usually discover that the operational friction has already eaten into the available value window. Fourth, align commissioner and provider incentives early. NHS England’s framework emphasises collaborative working and notes that without agreed financial arrangements all savings may accrue to the commissioner even though provider teams do the implementation work. The proposed use of national reference prices for prioritised biologicals is intended partly to solve this by creating a transparent incentive to switch while preserving a margin for clinically appropriate continued use of the reference product. Local leaders should not wait passively for national design to solve all execution issues. They should make the shared gain conversation part of the early planning. Fifth, track realised value and blockers monthly. Best value biologicals are ideal candidates for disciplined review because the cohorts, spend and timelines are often clearer than in other medicines optimisation areas. A useful monthly pack should show eligible patients, current uptake, target uptake, value delivered, operational issues, and any clinical or supply concerns that are slowing progress. If a switch is behind plan, the organisation needs to know quickly enough to intervene. There is also a wider strategic reason to take this seriously. Best value biologicals are one of the clearest examples of how NHS medicines value should work in the next phase: horizon scanning early, implementation planning before market entry, commissioner provider collaboration, shared use of national tools, and disciplined local execution. Teams that learn to do this well on biologicals will usually become better at other high value switching and contracting opportunities too. The NHS does not often get a productivity opportunity that is this visible, this policy backed and this measurable. That does not make delivery easy. It makes it worth managing properly. Boards should therefore resist two opposite mistakes. One is complacency: assuming that because the policy exists, the value will appear. The other is over complexity: surrounding the opportunity with so much governance and local reinvention that the implementation window closes. The better path is practical. Pick the molecule. Define the case. Resource the switch. Measure the rollout. Review the variance. Reinvest the gain. Best value biological medicines are not just another pharmacy workstream. In the current NHS environment, they are one of the most credible tests of whether providers and commissioners can convert medicines policy into real financial headroom without compromising care. That is exactly why they deserve board attention now.